Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RET-rearranged non-small-cell lung cancer and therapeutic implications.

Internal medicine journal - 1 Dec 2019

Loh Zoe, Mitchell Paul, John Thomas, Arulananda Surein

Abstract excerpt

First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Gene Rearrangement
Share to Piperidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Quinazolines

Source

Identifiers

PMID: 31808254
DOI: 10.1111/imj.14654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RET-rearranged non-small-cell lung cancer and therapeutic implications.PMID 31808254Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

Current management of RET rearranged non-small cell lung cancerSemantic proximity Read ↗

New Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung CancerSemantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusionSemantic proximity Read ↗

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.Semantic proximity Read ↗

Targeting molecular alterations in non-small-cell lung cancer: what's next?Semantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.